Breaking News Instant updates and real-time market news.

SAVE

Spirit Airlines

$39.08

-0.115 (-0.29%)

08:38
12/02/19
12/02
08:38
12/02/19
08:38

Spirit Airlines upgraded to Buy at Buckingham, price target raised to $50

Buckingham analyst Daniel McKenzie upgraded Spirit Airlines (SAVE) to Buy from Neutral with a price target of $50, up from $41. In a research note to investors, McKenzie says he downgraded the stock in September, arguing that Spirit's revenue outlook was set to worsen on the return of the 737 MAX (BA), the rollout of JetBlue's (JBLU) Fare Families 2.0 and competitive capacity that doubled, but says revenue worries are dissipating on reduced competitive capacity and revenue initiatives are set to finally gain traction in 2020. The analyst notes that the upgrade could prove "a bit early" until management can demonstrate the events are 21019 are isolated and recoverable.

  • 03

    Dec

SAVE Spirit Airlines
$39.08

-0.115 (-0.29%)

10/31/19
SBSH
10/31/19
INITIATION
Target $46
SBSH
Buy
Spirit Airlines initiated with a Buy at Citi
Citi analyst Stephen Trent initiated coverage of Spirit Airlines with a Buy rating and $46 price target.
10/31/19
SBSH
10/31/19
INITIATION
SBSH
Citi initiates the U.S. airlines sector, says Delta is top pick
Citi analyst Stephen Trent initiated the U.S. airlines sector in a note titled "Initiating coverage: Pick Your Routes Carefully." The analyst initiated Delta (DAL), United Airlines (UAL), and Spirit Airlines (SAVE) with Buy ratings, Southwest (LUV) with a Neutral rating, and American Airlines (AAL) with a Sell rating. Trent said that Delta was his top pick, citing attractive revenue diversity, relatively smooth earnings streams, and solid alliance networks. Trent is Neutral on Southwest as he believes the company's valuation relative to growth, along with 737 MAX risks, put the shares near fair value. The analyst has a Sell on American Airlines due to the company's high leverage, 2020 MAX redeployment, pilot contract negotiations, and valuations concerns.
11/19/19
SUSQ
11/19/19
INITIATION
Target $41
SUSQ
Neutral
Spirit Airlines initiated with a Neutral at Susquehanna
Susquehanna analyst Christopher Stathoulopoulos initiated coverage of Spirit Airlines with a Neutral rating and $41 price target.
12/02/19
BUCK
12/02/19
UPGRADE
BUCK
Buy
Spirit Airlines upgraded to Buy from Neutral at Buckingham
Buckingham analyst Daniel McKenzie upgraded Spirit Airlines to Buy from Neutral.

TODAY'S FREE FLY STORIES

VRTX

Vertex

$220.43

0.37 (0.17%)

, REGN

Regeneron

$372.10

-1.41 (-0.38%)

05:39
12/13/19
12/13
05:39
12/13/19
05:39
Recommendations
Vertex, Regeneron analyst commentary  »

Credit Suisse replaces…

VRTX

Vertex

$220.43

0.37 (0.17%)

REGN

Regeneron

$372.10

-1.41 (-0.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

OPI

Office Properties

$32.93

-1.02 (-3.00%)

05:36
12/13/19
12/13
05:36
12/13/19
05:36
Downgrade
Office Properties rating change  »

Office Properties…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VOLVY

Volvo

$0.00

(0.00%)

05:36
12/13/19
12/13
05:36
12/13/19
05:36
Hot Stocks
Volvo appoints Scott Rafkin as Chief Digital Officer »

Scott Rafkin, currently…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMGN

Amgen

$236.18

2.22 (0.95%)

05:36
12/13/19
12/13
05:36
12/13/19
05:36
Recommendations
Amgen analyst commentary  »

Amgen price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NDSN

Nordson

$162.94

-4.5 (-2.69%)

05:36
12/13/19
12/13
05:36
12/13/19
05:36
Upgrade
Nordson rating change  »

Nordson upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NBIX

Neurocrine

$111.41

-1.85 (-1.63%)

05:35
12/13/19
12/13
05:35
12/13/19
05:35
Downgrade
Neurocrine rating change  »

Neurocrine downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NDSN

Nordson

$162.94

-4.5 (-2.69%)

05:35
12/13/19
12/13
05:35
12/13/19
05:35
Downgrade
Nordson rating change  »

Nordson downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLPG

Galapagos

$214.12

-0.74 (-0.34%)

05:33
12/13/19
12/13
05:33
12/13/19
05:33
Downgrade
Galapagos rating change  »

Galapagos downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

GILD

Gilead

$67.64

0.5 (0.74%)

05:31
12/13/19
12/13
05:31
12/13/19
05:31
Downgrade
Gilead rating change  »

Gilead downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BIIB

Biogen

$293.92

1.71 (0.59%)

05:29
12/13/19
12/13
05:29
12/13/19
05:29
Upgrade
Biogen rating change  »

Biogen upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

REGN

Regeneron

$372.10

-1.41 (-0.38%)

05:26
12/13/19
12/13
05:26
12/13/19
05:26
Upgrade
Regeneron rating change  »

Regeneron upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHHBY

Roche

$0.00

(0.00%)

, EXEL

Exelixis

$17.68

0.05 (0.28%)

05:25
12/13/19
12/13
05:25
12/13/19
05:25
Hot Stocks
Genentech says Phase III IMspire150 study met primary endpoint of PFS »

Genentech, a member of…

RHHBY

Roche

$0.00

(0.00%)

EXEL

Exelixis

$17.68

0.05 (0.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Dec

HTHT

Huazhu Group

$34.86

0.92 (2.71%)

05:23
12/13/19
12/13
05:23
12/13/19
05:23
Upgrade
Huazhu Group rating change  »

Huazhu Group upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHHBY

Roche

$0.00

(0.00%)

05:22
12/13/19
12/13
05:22
12/13/19
05:22
Hot Stocks
Genentech says Phase III IMspire150 study met primary endpoint of PFS »

Genentech, a member of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Dec

SNAP

Snap

$14.45

0.22 (1.55%)

05:19
12/13/19
12/13
05:19
12/13/19
05:19
Upgrade
Snap upgraded to Outperform from Market Perform at JMP Securities »

JMP Securities analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INCY

Incyte

$92.79

-2.2 (-2.32%)

05:16
12/13/19
12/13
05:16
12/13/19
05:16
Recommendations
Incyte analyst commentary  »

Incyte risk/reward…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

PCG

PG&E

$11.75

-0.38 (-3.13%)

05:14
12/13/19
12/13
05:14
12/13/19
05:14
Hot Stocks
PG&E files amended plan of reorganization »

PG&E Corporation and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

SRPT

Sarepta

$100.39

-1.15 (-1.13%)

05:12
12/13/19
12/13
05:12
12/13/19
05:12
Recommendations
Sarepta price target raised to $210 from $185 at Piper Jaffray »

Piper Jaffray analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOVE

Lovesac

$11.81

-2.68 (-18.50%)

05:07
12/13/19
12/13
05:07
12/13/19
05:07
Downgrade
Lovesac rating change  »

Lovesac downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

  • 19

    Dec

TDOC

Teladoc

$77.06

-0.36 (-0.46%)

05:04
12/13/19
12/13
05:04
12/13/19
05:04
Initiation
Teladoc initiated  »

Teladoc initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TTMI

TTM Technologies

$13.79

0.19 (1.40%)

05:01
12/13/19
12/13
05:01
12/13/19
05:01
Upgrade
TTM Technologies rating change  »

TTM Technologies upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FII

Federated Investors

$34.41

0.41 (1.21%)

05:01
12/13/19
12/13
05:01
12/13/19
05:01
Downgrade
Federated Investors rating change  »

Federated Investors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMK

AssetMark Financial

$27.31

0.42 (1.56%)

05:00
12/13/19
12/13
05:00
12/13/19
05:00
Upgrade
AssetMark Financial rating change  »

AssetMark Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VCTR

Victory Capital

$21.68

0.235 (1.10%)

05:00
12/13/19
12/13
05:00
12/13/19
05:00
Downgrade
Victory Capital rating change  »

Victory Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EV

Eaton Vance

$47.08

0.395 (0.85%)

05:00
12/13/19
12/13
05:00
12/13/19
05:00
Upgrade
Eaton Vance rating change  »

Eaton Vance upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.